NVO
Citi hits the brakes
Novo Nordisk got a fresh reality check as Citi lowered its price target to DKK 296, pointing to limited margin growth. That’s not exactly the kind of note investors frame and hang on the wall.
Why this matters
When analysts start talking about margin pressure, they’re basically asking whether all that revenue growth can turn into real profit growth — the part the market actually gets excited about. In Novo’s case, the company is still in the center of the obesity-and-diabetes gold rush, but Citi seems less convinced the profits will expand as smoothly as the bull case suggests.
The investor takeaway
A price-target cut doesn’t change Novo’s business overnight, but it can change the mood music. If margins stay pinned down, the stock may need even stronger sales growth, better operating leverage, or fresh pipeline wins to keep investors engaged.
Big picture: Novo still has plenty going for it, but Citi is basically reminding the market that even the hottest growth stories can trip over the boring stuff like margins.